TNFRSF17 and plasma cell myeloma: In pretreated multiple myeloma, the BsAbs teclistamab, elranatamab and alnuctamab have shown efficacy in binding CD3 and BCMA, as well as the BsAbs talquetamab binding CD3 and GPRC5D [55,56].